Precision today, access tomorrow
Uniquely designed with an open-frame and supra-annular leaflets, the ACURATE neo2™ Aortic Valve System delivers the performance you expect today, without restricting the access you demand tomorrow.1,2
Treat your patients today while protecting them for the future with:
Moderate PVL
0% Severe PVL
18.9% Mild PVL
Permanent pacemaker rate †
Procedural
success rate
Mean gradient
All cause mortality
All stroke
0% disabling stroke
at 30 days
See the unique open-frame, supra-annular design in action
Proven features
Open frame
Provides unrestricted access for future interventions
Supra-annular leaflets
Achieve large EOAs and single-digit gradients1
Precise positioning
Upper and lower-crown anchoring provides first-time, precise procedures
Active PVseal™
60% larger* sealing skirt conforms to the native aortic annulus to minimize PVL
* ACURATE neo2 Valve compared to previous generation, ACURATE neo™ Valve
"PAR (Paravalvular Aortic Regurgitation) reduction demonstrated with ACURATE neo2 is very impressive and underlines the efficacy of the [valve's] active sealing skirt."
- Dr Won-Keun Kim and Prof. Helge Möllmann
JACC: Cardiovascular Interventions "Neo to Neo2 - a tiny detail with considerable impact."
Explore our 3D sketch pad tool
Accessories and other products
SENTINEL™ Cerebral Protection System
Protected TAVR™ with SENTINEL Cerebral Protection System (CPS) gives you the power to reduce stroke.
iSLEEVE™ Expandable Introducer Set
The low-profile iSLEEVE Introducer expands patient access into smaller and increasingly complex vasculature.
SAFARI2™ Pre-Shaped TAVI Guidewire
Available in three sizes, SAFARI2 provides streamlined device delivery through optimized rail support as well as enhanced wire predictability.
*PAR (paravalvular aortic regurgitation) assessed pre-discharge in next-generation ACURATE neo2™ Valve vs. ACURATE neo™.
**Average time to obtain commissural alignment.
† Among pacemaker-naïve patients. Among all patients, implanted pacemaker rate= 6.1%
1. Möllmann H, Holzhey DM, Hilker M, et al. The ACURATE neo2 Valve System for transcatheter aortic valve implantation: 30-day and 1-year outcomes. Clin Res Cardiol. 2021;110:1912–1920.
2. Reobtain Coronary Ostia Cannulation Beyond Transcatheter Aortic Valve Stent (RE-ACCESS); NCT04026204. J Am. Coll. Cardiol. Intv.. 2020.
3. Buono A, et al. TAVI with self-expanding ACURATE neo2: Postprocedural hemodynamic and short-term clinical outcomes. JACC Cardiovasc Interv. 2022. doi: 10.1016/j. jcin.2022.02.027
4. Meduri C, et al. The neo-ALIGN study. Presented at Euro PCR 2022.
5. Kim W., et al; Clinical outcomes of the ACURATE neo2 transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study, EuroIntervention 2022. DOI: 10.4244/EIJ-D-22-00914.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. Product available in the European Economic Area (EEA) only. Please check availability with your local sales representative or customer service
